Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.53 |
| ▸ | CAMK1D | Q8IU85 | 7/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.50 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.50 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12085437 | 0.91 | CAMK1D (0.55) | SYKCAMK1DKCNH2AURKBMAPK3 | |
| SCHEMBL12085422 | 0.88 | SYK (0.60) | SYKCAMK1DKCNH2AURKBMAPK3 | |
| SCHEMBL12085443 | 0.87 | SYK (0.53) | SYKCAMK1DKCNH2AURKBMAPK3 | |
| SCHEMBL12085291 | 0.86 | SYK (0.57) | SYKCAMK1DKCNH2AURKBMAPK3 | |
| SCHEMBL12085331 | 0.83 | CAMK1D (0.62) | SYKCAMK1DKCNH2AURKBMAPK3 | |
| SCHEMBL12085292 | 0.81 | SYK (0.66) | SYKCAMK1DKCNH2AURKBMAPK3 | |
| SCHEMBL12085277 | 0.80 | CAMK1D (0.59) | SYKCAMK1DKCNH2AURKBMAPK3 | |
| SCHEMBL14670756 | 0.79 | CAMK1D (0.63) | SYKCAMK1DKCNH2AURKBMAPK3 | |
| SCHEMBL12085312 | 0.75 | CAMK1D (0.62) | SYKCAMK1DKCNH2AURKBMAPK3 | |
| SCHEMBL12085290 | 0.74 | SYK (0.54) | SYKCAMK1DKCNH2AURKBMAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK2 | SYK 1/4885CAMK1D 778/4885KCNH2 2573/4885 |
| US-20090298823-A1 | Inhibitors of protein kinases | SYK, BTK, JAK2 | SYK 1/4885CAMK1D 778/4885KCNH2 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.